Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
MGC Pharmaceuticals Ltd
Master Supply & Distribution agreement signed with Swiss PharmaCan AG for exclusive worldwide[1] distribution of ArtemiCTM Rescue
Key Highlights:
· Minimum three (3) year exclusive worldwide1 supply and distribution agreement signed with leading European nutraceuticals producer and distributor, Swiss PharmaCan AG, for the distribution of ArtemiC™ Rescue as a food supplement
· This agreement follows the completion of a successful phase II double-blind, placebo-controlled clinical trial on 50 COVID-19 patients across Israel and India that met all its primary and secondary endpoints
· Agreement includes minimum wholesale order quantity to MGC Pharma of 40,000 units of ArtemiC™ Rescue per quarter
· Initial wholesale order of 10,000 units received by MGC Pharma, which has a total retail market value of US$850,000 for Swiss PharmaCan AG
· MGC Pharma to also produce and provide daily dosage immune support supplement ArtemiC™ Support, for daily use.
· Swiss PharmaCan AG to exclusively distribute ArtemiC™ Rescue and ArtemiC™ Support worldwide1, with specific focus on countries currently reporting high numbers of COVID-19
· The Company has sufficient manufacturing capacity at its production facility in Slovenia to produce commercial scale batches of ArtemiC™ Rescue and ArtemiC™ Support for distribution by Swiss PharmaCan AG
· Additionally, Swiss PharmaCan AG has already secured agreement with Relay Medical Corp. (CSE: RELA) and Glow LifeTech Ltd. for exclusive North American and Caribbean sales and distribution rights for ArtemiC™ Rescue and ArtemiC™Prevention
· Swiss PharmaCan AG has also secured ONASIS Holdings Corp. (OTC: ONSS) as Master Distributor of ArtemiC™ Rescue and ArtemiC™ Prevention through their channels in USA and Central America.
MGC Pharmaceuticals Ltd (ASX, LSE: MXC, 'MGC Pharma' or 'the Company'), a European based bio-pharma company specialising in the production and development of phytocannabinoid-derived medicines, is pleased to announce it has signed an exclusive master supply and distribution agreement (the 'Agreement') with leading European nutraceutical producer and distributor, Swiss PharmaCan AG ("SPC") for the sale and distribution of the Company's food supplement ArtemiC™ Product line. ArtemiC™ incorporates SPC's MyCell Enhanced™ delivery system technology.
ArtemiC™ is a clinically tested food supplement (nutraceutical, dietary supplement, natural health product) containing four natural based ingredients consisting of Artemisinin, Curcumin, Boswellia serrata, and Vitamin C.
This Agreement represents the first sales of ArtemiC™ as a food grade product and provides MGC Pharma direct access to the large and rapidly growing markets that are still reporting high numbers of COVID-19 cases.
The signing of this distribution agreement follows the completion of a phase II double-blind, placebo-controlled clinical trial on 50 C
Last rns does sound promising.hopefully hear more end of Feb.
This is old news,Gareth Cave has already have the box of masks to the hospital when he had his cancer check up last year so why Tom W is writing about it now is a complete waste of time
I agree but that rns was worth well more than 10% rise.im struggling to find out what news is going to make this rise to recent highs bar sales
£5,hope you mean 5 million pound
Can someone please explain why Tom is so low when they are producing oil ? I've looked through twitter rns and news but can't work it out?
Early stages.they better hurry up and do DD so we can move forward before March delisting
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has successfully completed the development of its CDX antibody with a leading global pharmaceutical company ("GlobalCo"). As a result of the Company's successful collaboration with GlobalCo, the Company has chosen a clone of its CDX antibody that is ready for investigational new drug ("IND") application-enabling studies, a significant step toward clinical trials.
On 14 May 2018, the Company announced a collaboration with GlobalCo to work on its CDX antibody. Under the Agreement, which stipulated that GlobalCo's identity remain anonymous for the time being, Hemogenyx Pharmaceuticals received, free of charge, technical support, access to advanced methods of discovering, developing and engineering antibodies, and certain intellectual property necessary for the successful preclinical development of the Company's lead candidate bi-specific CDX antibody for the treatment of acute myeloid leukemia ("AML"). This work complemented the Company's own development work that was being undertaken.
With the phase of the Agreement relating to the development of the antibody completed, under the Agreement, as of 11 January 2021, GlobalCo has three months to exercise an option to license the Company's intellectual property necessary to exploit the CDX antibody on an exclusive worldwide basis ("Option"). In the event GlobalCo and Company are unable to reach an exclusive licensing agreement within six months of GlobalCo's exercise of the Option, if any, or if GlobalCo does not exercise the Option, Hemogenyx Pharmaceuticals will have three months to exercise an option to license the GlobalCo's intellectual property necessary to exploit the CDX antibody on an exclusive worldwide basis, followed by six months to reach an exclusive licensing agreement.
In either scenario, the Directors are confident that a successful outcome will be achieved to take the development of the CDX antibody forward toward clinical trials. In the meantime, the Company and GlobalCo will continue developing the CDX antibody asset.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:
"We are extremely pleased with the outcome of our collaboration with GlobalCo, which has resulted in a CDX antibody that is ready to be developed for clinical trials. I am very proud of the Company's team of scientists who, without a doubt, have proven that Hemogenyx Pharmaceuticals is capable of performing cutting edge research and development of the highest calibre. The completion of the development of the CDX antibody with GlobalCo is a key milestone on our path to creating an effective treatment for patients suffering from AML, and we look forward to entering into the next phase of negotiations with GlobalCo."
About AML
AML, the most common type of acute leukemia in adults, has
They cant legally force him to sell so why would he sell to buy back at a higher price ?
Amz,does that mean,no news until commissioned?
TAKE A CHILL PILL WILL
I thought it was funny tbh.there no harm in making Jokes as long as the sp is going in the correct direction.
Haha " very robustly" ,what you got planned Steve,are we going to call the police like rms Bod announced.the best outcome i can see is to get the egm,get warrants squished or moved to 7p exercise price.we do not need such a stupid amount of dilution in the company when we are so close to making a huge revenue.volz didn't get involved on hearsay.this product is huge and will change alot of peoples lives.we need to get the bods board fixed before they destroy this shares with the silly amount off warrants they want to issue.lastly the bod has no rite to put GCs signature on the placing rns as he is not on the board.trying is bring down a man's reputation like thats is a joke,especially whilst planning to lower his percentage in the company.hopefully hear how this virtual meeting went soon or at least a delivery update ffs.
Probably Trevor brown after selling his whole holding for bags more than today after saying he wouldn't
What are you onabout.
TB has milked this company for his own gain and destroyed the sp in the process.he needs to go and as of Dr Cavehe should of known the placing was coming when he seen they signed his name without his consent.
Just sent an email to Jonathan.hall@egremont.com and added my holding in favour of dr cave support ??
Welcome to aim,where the profits are high and the risk is higher lol
Wish I did.cant seem to find any information since it got de-listed.does anyone know of an announcement from the company regarding what they was looking to invest in.wish it was RMS
They've done so well to make a life changing mask so cheap.this is the begining